Topoisomerase IIβ Cleavable Complexes and Mitochondrial Genotoxic Stress in Hepatic Tissue
Doxorubicin (Adriamycin) functions clinically as a potent broad-spectrum anthracycline; however, its administration frequently induces organ-specific toxicities characterized by cellular senescence rather than rapid cytotoxic clearance [1]. In post-mitotic and quiescent parenchymal cells, doxorubicin exhibits marked reactivity against DNA topoisomerase IIβ (TOP2B), establishing persistent enzyme-DNA cleavable complexes that stall transcriptional elongation and generate sustained double-strand breaks (DSBs) marked by γ-H2AX foci [1][2]. Unlike actively cycling malignancies that undergo rapid caspase-dependent apoptosis following topoisomerase IIα poisoning, quiescent non-transformed hepatocytes exposed to low clinical concentrations (50–250 nM) activate robust cell cycle checkpoints governed by ATM/ATR kinases [2][3]. Concurrently, doxorubicin displays a high binding affinity for cardiolipin, an anionic phospholipid concentrated within the inner mitochondrial membrane (IMM) [1]. This physical partitioning decouples oxidative phosphorylation complexes I and III, initiating electron leakage directly to molecular oxygen and driving the generation of intramitochondrial superoxide anions at sub-micromolar thresholds (EC50 ~120 nM) [2][3].
In primary mouse hepatocytes, this organelle-targeted genotoxic stress induces displacement of mitochondrial transcription factor A (TFAM), provoking extensive mitochondrial DNA (mtDNA) depletion and uncoupling nuclear-encoded mitochondrial transcripts from organelle translation [2]. Comparative pharmacology confirms that doxorubicin exhibits unique capacity to establish this dual nuclear-mitochondrial genotoxic arrest relative to conventional DNA alkylators or antimetabolites, as benchmarked in Table 1. In cultures of human HH4 hepatocytes, sub-apoptotic doxorubicin regimens selectively elevate non-transferrin-bound intracellular iron pools, catalyzing Fenton chemistry without immediately prompting canonical BAX/BAK pore opening or cytochrome c release [3]. Consequently, hepatic parenchyma remains metabolically active yet irreversibly arrested, developing stable morphological alterations, permanent replicative arrest, and extensive cellular hypertrophy characteristic of therapy-induced senescence [1][3].
CLPP Endopeptidase Downregulation Disrupts Matrix Proteostasis Prior to Cell Cycle Arrest
Mitochondrial matrix proteostasis relies on ATP-dependent proteolytic machineries to clear damaged, oxidized, and misfolded proteins generated under genotoxic stress [1][4]. Central to this matrix surveillance system is the caseinolytic mitochondrial matrix peptidase chaperone subunit (CLPP), which cooperates with the AAA+ chaperone CLPX to degrade redundant polypeptides [1]. Following prolonged doxorubicin exposure, reactive oxygen species induce severe membrane lipid peroxidation, generating abundant alpha,beta-unsaturated aldehydes such as 4-hydroxynonenal (4-HNE) [4][5]. These electrophilic species form direct covalent Michael adducts with nucleophilic histidine and cysteine residues adjacent to the catalytic Ser-His-Asp triad of CLPP, suppressing its endopeptidase velocity [1][4]. Fluorogenic cleavage assays using Ac-WLA-AMC or Suc-LY-AMC peptides reveal a >65% reduction in baseline CLPP hydrolytic activity in senescent liver extracts [1].
The loss of CLPP activity disrupts the stoichiometry of the electron transport chain (ETC) [1][5]. Nuclear-encoded respiratory complex subunits—principally NDUFS3 of complex I and SDHA of complex II—fail to incorporate efficiently into nascent holoenzymes and accumulate as insoluble matrix aggregates [1]. This matrix proteotoxicity develops before the classic upregulation of cell cycle inhibitors [4]. In human AC16 cells and IHH parenchymal cultures, early CLPP inactivation compromises the basal oxygen consumption rate (OCR) and limits the spare respiratory capacity, precipitating an energy deficit characterized by elevated cellular lactate-to-pyruvate ratios and reduced ATP synthesis [4][5]. Because LONP1 protease capacity remains insufficient to compensate for CLPP deficiency during ongoing anthracycline exposure, misfolded polypeptides persist within the matrix, initiating retrograde mitochondrial stress cascades that lock hepatocytes into sustained growth arrest [1][5].
Suppression of Canonical UPRmt Transducers Accelerates the SASP Secretome
The accumulation of matrix proteotoxic aggregates typically triggers the mitochondrial unfolded protein response (UPRmt), a transcriptional rescue program designed to restore organelle proteostasis [1]. Canonical UPRmt activation requires the stabilization and nuclear translocation of Activating Transcription Factor 5 (ATF5) in mammals, which transcribes mitochondrial chaperones including HSP60 (HSPD1), mtHSP70 (GRP75/HSPA9), and the proteases CLPP and LONP1 [1][6]. In decompensated liver tissue and doxorubicin-treated hepatocytes, this adaptive loop fails [1]. ATF5 nuclear translocation is attenuated under sustained low-dose doxorubicin exposure, preventing the compensatory transcription of HSP60 and mtHSP70 [1]. The unbuffered accumulation of misfolded polypeptides exacerbates outer mitochondrial membrane instability, facilitating the herniation of fragmented mtDNA into the cytoplasm [6][7].
Once displaced into the cytosol, oxidized mtDNA engages cyclic GMP-AMP synthase (cGAS), activating the stimulator of interferon genes (STING) adaptor protein [7]. This signaling intermediate promotes TBK1-dependent phosphorylation and nuclear translocation of NF-κB p65, in parallel with the stress-induced activation of C/EBPβ [7]. This transcription factor complex drives the synthesis and secretion of the senescence-associated secretory phenotype (SASP), a pathogenic cocktail enriched in pro-inflammatory and pro-fibrogenic cytokines, including IL-1α, IL-6, PAI-1 (SERPINE1), and CCL2 [1][7]. In co-culture models utilizing hepatic stellate LX-2 cells, secretomes isolated from doxorubicin-arrested hepatocytes stimulate alpha-smooth muscle actin (α-SMA) assembly and collagen type I expression, establishing that anthracycline-induced UPRmt collapse drives bystander fibrogenesis across the hepatic microenvironment [3][7].
SA-β-Gal Quantification and Biomarker Signatures of Therapy-Induced Hepatic Senescence
Therapy-induced senescence in hepatic tissue is characterized by an irreversible exit from the cell cycle coupled with distinct cytochemical phenotypes [1][2]. The loss of proliferative capacity is reinforced through the transcriptional activation of cyclin-dependent kinase inhibitors CDKN1A (p21Cip1) and CDKN2A (p16INK4a) [2][3]. Elevated p21Cip1 complexes directly with cyclin E/CDK2, repressing the phosphorylation of retinoblastoma protein at Ser807/811 and maintaining E2F transcription factors in a constitutively repressed state [3][6]. To definitively verify senescent conversion and distinguish it from transient, reversible G0 quiescence, experimental protocols require orthogonal biomarker validations, including the arrest of 5-ethynyl-2'-deoxyuridine (EdU) incorporation and the selective loss of nuclear lamin B1 (LMNB1) [2][6].
The primary enzymatic marker for identifying this state is senescence-associated beta-galactosidase (SA-β-gal) activity, driven by elevated lysosomal mass and the overexpression of lysosomal beta-D-galactosidase encoded by the GLB1 gene [1][2]. In primary hepatocyte preparations, SA-β-gal activity must be assayed strictly at pH 6.0 [1][2]. Cytochemical staining using 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) at pH 6.0 avoids the false-positive signals generated by endogenous lysosomal hydrolases that operate at acidic lysosomal pH 4.0–4.5 [2]. Quantitative evaluation is achieved using the lipophilic fluorogenic substrate 5-dodecanoylaminofluorescein di-β-D-galactopyranoside (C12FDG) via flow cytometry, which reveals an approximate 4- to 7-fold increase in mean fluorescence intensity in doxorubicin-treated cells relative to controls [3][6]. Furthermore, senescent hepatocytes display profound iron accumulation detectable via FerroOrange probes, along with the downregulation of cellular antioxidant systems, establishing a stable biomarker panel that delineates persistent hepatic senescence from transient injury [3].
Pharmacological CLPP Activation Reverses Doxorubicin-Driven Senescent Transitions
Because suppression of CLPP activity represents a key vulnerability enabling mitochondrial proteotoxicity, allosteric restoration of this matrix peptidase offers a targeted therapeutic strategy to disrupt anthracycline-induced hepatocyte arrest [1]. Structurally, functional CLPP forms a barrel-shaped tetradecameric complex containing two heptameric rings enclosing an internal proteolytic chamber [1]. Small-molecule acyldepsipeptides (ADEPs) and imipridone derivatives, including ONC201, bind selectively to hydrophobic pockets on CLPP heptamers, inducing an open-gate conformation that mimics CLPX-chaperone docking and stimulates ATP-independent proteolysis of unstructured polypeptide substrates [1][8]. In preclinical models of doxorubicin hepatotoxicity, administration of ONC201-class agonists or transgenic CLPP reconstitution prevents the accumulation of misfolded NDUFS3 and SDHA, restoring matrix clearance mechanisms [1].
Reactivation of CLPP proteolytic flux restores mitochondrial membrane potential (ΔΨm) and elevates basal oxygen consumption, rescuing ATP production toward physiological baselines [1][8]. Furthermore, the clearance of matrix aggregates diminishes mitochondrial reactive oxygen species production and limits the cytosolic leakage of damaged mtDNA, repressing the downstream cGAS-STING-NF-κB axis [7][8]. Consequently, the secretion of critical SASP components, including IL-6 and CCL2, is attenuated by >60% in treated parenchymal populations [1]. Pharmacological reactivation of CLPP also decreases the proportion of C12FDG-positive, SA-β-gal-expressing hepatocytes without interfering with the antineoplastic efficacy of doxorubicin against extrahepatic tumor xenografts [1][8]. Restoring matrix peptidase activity and re-establishing UPRmt proteostasis thus presents an actionable intervention to protect the hepatic parenchyma during anthracycline-based chemotherapy regimens [1][8].